Cabaletta Bio's Rese-cel Shows Promising Safety and Efficacy in Autoimmune Disease Trials
Key Insights
Cabaletta Bio will present updated clinical data on rese-cel at upcoming scientific meetings in February 2025, showcasing its potential in autoimmune diseases.
Early data from the first 10 patients dosed with rese-cel show a favorable safety profile with minimal cytokine release syndrome or neurotoxicity.
Cabaletta Bio plans to meet with the FDA in the first half of 2025 to discuss the registrational pathway for rese-cel.
Cabaletta Bio, a clinical-stage biotechnology company, is set to present updated clinical data on its lead candidate, resecabtagene autoleucel (rese-cel), at two upcoming scientific conferences in February 2025. The presentations will feature safety, translational data, and clinical outcomes from the first 10 patients treated with rese-cel across multiple ongoing clinical trials within the RESET clinical development program.
The data, gathered from the Phase 1/2 RESET trials, will be presented at the American Association for the Advancement of Science (AAAS) Annual Meeting in Boston and the International Conference on Lymphocyte Engineering in Munich. These presentations will highlight the potential of rese-cel, a CD19 (search)-CAR T cell therapy, in treating autoimmune diseases such as myositis (search), systemic lupus erythematosus (search) (SLE (search)), and systemic sclerosis (search) (SSc (search)).
Favorable Safety Profile
According to Cabaletta Bio, the initial safety data from the first 10 patients dosed with rese-cel is encouraging. Ninety percent of patients experienced either no cytokine release syndrome (CRS) or only grade 1 CRS (fever), and 90% experienced no immune effector cell-associated neurotoxicity syndrome (ICANS). This favorable safety profile is crucial for CAR T-cell therapies, which are often associated with significant toxicities.
Strategic Priorities and Upcoming Milestones
Cabaletta Bio is actively engaging with the FDA to define a registrational path for rese-cel, leveraging indication-specific trials to expedite the therapy's advancement. The company plans to meet with the FDA in the first half of 2025 to discuss registrational trial designs based on emerging clinical and translational data.
Steven Nichtberger, M.D., CEO of Cabaletta, stated, "Our clinical execution in 2024 allowed us to accelerate timelines for registrational discussions and demonstrate the potential of rese-cel to deliver immunosuppressant-free, compelling clinical responses in patients with active, refractory autoimmune disease."
Expanding Clinical Development Program
Cabaletta Bio is expanding the RESET clinical development program, with 21 patients enrolled across 44 active clinical sites in the U.S. and Europe as of December 31, 2024. The program includes multiple disease-specific cohorts, such as the RESET-PV trial evaluating rese-cel without preconditioning in pemphigus vulgaris (search) patients, and the RESET-MS trial for multiple sclerosis (search), which has received Fast Track Designation from the FDA.
About Rese-cel
Rese-cel is an investigational 4-1BB-containing fully human CD19 (search)-CAR T cell therapy designed to deplete CD19-positive B cells transiently and completely. This approach aims to reset the immune system, potentially leading to durable clinical responses without the need for chronic immunosuppression. The therapy is being evaluated in various autoimmune diseases within the RESET program, spanning rheumatology, neurology, and dermatology.
Financial Position
Cabaletta Bio reported unaudited cash and cash equivalents of $164 million at the end of 2024, which is expected to fund operations into the first half of 2026.